The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing of option and ...

Continued Maintenance Investment to Drive Free Cash Flow; High-Graded Portfolio Bolsters Financial Resiliency Highlights: ...

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Landstar System, Inc. (“Landstar” or the “Compan ...

Detailed price information for Landstar System (LSTR-Q) from The Globe and Mail including charting and trades.

Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2025, were $4.4 million, compared to $15.8 million for the same period in 2024. The decrease was due ...

Introduction The global shift toward sustainability and climate-related financial disclosures has seen the International Financial Reporting Standards (IFRS) Foundation introduce two new ...

ST Xinchao announced that it was placed under investigation by the China Securities Regulatory Commission for failing to disclose its periodic report (2024 annual report) within the specified time ...

Continued Maintenance Investment to Drive Free Cash Flow; High-Graded Portfolio Bolsters Financial Resiliency Highlights: Generated cash from operating activities ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...

Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in ...

Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) ...